Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 35 Carcinoma, Hepatocellular 28 Stomach Neoplasms 12 Neoplasm Metastasis 12 Nasopharyngeal Carcinoma 11 Neoplasms 10 Esophageal Neoplasms 10 Melanoma 8 Esophageal Squamous Cell Carcinoma 8 Colorectal Neoplasms 8 Recurrence 7 Lung Neoplasms 7 Breast Neoplasms 7 Biliary Tract Neoplasms 7 Triple Negative Breast Neoplasms 6 Small Cell Lung Carcinoma 5 Rectal Neoplasms 5 Pancreatic Neoplasms 5 Head and Neck Neoplasms 5 Cholangiocarcinoma 5 Squamous Cell Carcinoma of Head and Neck 4 Locally Advanced Rectal Cancer 4 Colonic Neoplasms 4 Carcinoma, Renal Cell 4 Advanced NSCLC 4 Urinary Bladder Neoplasms 3 Sarcoma 3 Liver Neoplasms 3 Leukemia, Myeloid, Acute 3 Hyperthermia 3

Interventions

pembrolizumab 1 olaparib 1 ceralasertib 1 apatinib 1 anlotinib 1 Immune Checkpoint Inhibitors 1 Etoposide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × SCLC × Immune Checkpoint Inhibitors × Clear all

NCT07110103 2026-02-27

JACKPOT38

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡